RMD · News · 20260807N

Astral FDA Recall

RESMED INC · 2026-08-07 · Importance 78 · Surprise 100

ResMed suspended new sales of Astral ventilators in fiscal 2027 following an FDA recall and field safety action. The action is expected to reduce fiscal 2027 revenue by approximately $75 million, while company resources are redirected toward repairing existing devices. The sales suspension creates a regulatory and execution headwind for the respiratory-care portfolio through FY2027.

Key facts

• ResMed suspended new sales of its Astral ventilator following an FDA recall/field safety action. source